Bolt Biotherapeutics, Inc. BOLT
Our mission is to harness the power of the immune system to improve lives and eradicate cancer. This often means that our product candidates take new and unproven approaches to treating cancer. We believe that taking smart risks is critical to making breakthroughs. Our pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. Our various approaches use pattern recognition receptors expressed by the innate immune system to help the body eliminate tumor cells as part of a productive anti-cancer response. Our proprietary Boltbody Immune-Stimulating Antibody Conjugate, or ISAC, platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. We believe this approach has the potential to create products that work with a patient's own immune system, resulting in anti-cancer activity with acceptable tolerability. Having explored more than one thousand distinct linker-payloads and multiple tumor targets, we know the importance of both the linker-payload and the antibody and have developed a library of linker-payloads for use in our own development programs and in our collaborations.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $7.7M | $7.7M | $7.9M | $5.7M | $1.3M | $231.0K | — |
| R&D | $28.5M | $57.5M | $61.5M | $73.1M | $75.7M | $40.4M | — |
| SG&A | $13.8M | $18.5M | $22.5M | $22.9M | $18.4M | $9.1M | — |
| Total operating expenses | $43.8M | $80.7M | $84.1M | $96.0M | $94.0M | $49.4M | — |
| Operating income | -$36.1M | -$73.0M | -$76.2M | -$90.3M | -$92.8M | -$49.2M | — |
| Pre-tax income | -$33.4M | -$63.1M | -$69.2M | -$88.1M | -$98.6M | -$60.7M | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$33.4M | -$63.1M | -$69.2M | -$88.1M | -$98.6M | -$60.7M | — |
| EPS, basic | -17.85 | -33.06 | -1.83 | -2.36 | -2.97 | — | — |
| EPS, diluted | -17.85 | -33.06 | -1.83 | -2.36 | -2.97 | -28.89 | — |
| Shares, diluted (wtd. avg.) | 1.9M | 1.9M | 37.8M | 37.4M | 33.2M | 2.0M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $11.7M | $7.2M | $10.8M | $9.2M | $27.4M | $5.5M | — |
| Short-term investments | $15.8M | $40.1M | $91.4M | $159.6M | $158.8M | $17.3M | — |
| Total current assets | $30.3M | $50.8M | $105.7M | $172.7M | $189.2M | $25.4M | — |
| Property, plant and equipment | $1.2M | $3.1M | $5.0M | $6.5M | $6.2M | $4.1M | — |
| Total assets | $56.7M | $99.6M | $159.8M | $227.8M | $307.7M | $46.5M | — |
| Accounts payable | $1.4M | $1.5M | $3.0M | $3.6M | $3.6M | $1.6M | — |
| Total current liabilities | $8.4M | $15.9M | $20.5M | $23.1M | $21.3M | $11.3M | — |
| Total liabilities | $30.2M | $42.4M | $47.0M | $56.3M | $57.6M | $46.2M | — |
| Retained earnings | -$460.8M | -$427.4M | -$364.3M | -$295.1M | -$207.0M | -$108.4M | — |
| Total equity | $26.5M | $57.2M | $112.7M | $171.5M | $250.1M | -$104.9M | -$45.8M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$39.9M | -$61.3M | -$69.5M | -$76.5M | -$57.1M | -$47.3M | — |
| Depreciation and amortisation | $1.3M | $1.8M | $1.9M | $1.7M | $1.2M | $611.0K | — |
| Stock-based compensation | $2.8M | $7.4M | $9.2M | $9.6M | $8.5M | $1.4M | — |
| Capital expenditure | $72.0K | $41.0K | $206.0K | $2.0M | $2.3M | $3.3M | — |
| Investing cash flow | $44.3M | $57.6M | $71.0M | $57.9M | -$232.2M | -$20.6M | — |
| Financing cash flow | $19.0K | $108.0K | $253.0K | $503.0K | $311.1M | $39.6M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-104121.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $231.0K | $1.3M | $5.7M | $7.9M | $7.7M | $7.7M |
| Gross profit | — | — | — | — | — | — | — |
| Net income | — | -$60.7M | -$98.6M | -$88.1M | -$69.2M | -$63.1M | -$33.4M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Results announced Item 2.02
- Restructuring or exit costs A restructuring: layoffs, a plant closure, a business being wound down. Item 2.05
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced Item 2.02
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Other event Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |